We are live on ! Find out more

Fidelity MSCI Health Care Index ETF

FHLC

Market cap $3.92B

88.37 USD

+1.77

2.04%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

88.50

+0.13

0.15%

1 day

2.04%

5 days

2.26%

1 month

6.95%

3 months

9.78%

6 months

28.18%

Year to date

18.52%

1 year

27.39%

5 years

32.69%

10 years

175.98%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.7%

Neutral 57.1%

Negative 7.1%

The Motley Fool

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?

Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for the iShares Biotechnology ETF. iShares Biotechnology ETF is more concentrated, with 87% of its portfolio in biotechnology stocks.

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?

The Motley Fool

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

The Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio and a more diversified portfolio than the State Street SPDR S&P Biotech ETF. The State Street SPDR S&P Biotech ETF experienced a much deeper maximum drawdown over the last five years but outperformed on a 1-year total return basis.

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech

The Motley Fool

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

5 Undervalued Oncology Stocks Wall Street Is Overlooking

The Motley Fool

Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?

Fidelity MSCI Health Care Index ETF has a significantly lower expense ratio than iShares Global Healthcare ETF. iShares Global Healthcare ETF provides exposure to international healthcare markets, whereas the Fidelity fund focuses on U.S. equities.

Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure?

Zacks Investment Research

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Tackle Market Uncertainty With Strategic Healthcare Exposure

With much of the attention in the capital markets directed towards the technology sector, it's easy to forget other sectors like healthcare. However, it's key to consider other sectors within your portfolio to help hedge against heavy volatility.

Tackle Market Uncertainty With Strategic Healthcare Exposure

The Motley Fool

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

The Motley Fool

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

The Fidelity MSCI Health Care Index ETF features a lower expense ratio of 0.08% and a higher dividend yield of 1.2%. The Invesco Nasdaq Biotechnology ETF has delivered a higher 1-year total return of 56.4% but carries a more significant maximum drawdown of 37.9%.

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

See News Rankings

Price charts implemented using Lightweight Charts™